Life Sciences Industry Update

At LSC we specialise only in Life Sciences and always keep up to date with leading news, projects and all that’s going on in the industry. As the sector sees continued rapid growth it’s easy to miss some of the major announcements. To make things easier and to ensure you too are well informed we’ve selected and summarised this month’s top Irish Life Science industry news stories below.

Eurofins announce 150 high tech jobs for Dublin

150 high tech jobs are on the way for Dublin, as Eurofins announce plans to establish a global software engineering centre in Sandyford as part of an IT investment expansion. The Life Sciences company have had operations in Ireland since 2003 and carry out clinical diagnostics, biopharma, agro-science and food and beverage testing. The new team in Sandyford will be responsible for work on DevOps, virtualisation and cloud strategy.  Full article >>

DePuy Synthes to create 30 jobs as part of €36m investment in Cork

Plans have been announced for a €36 million investment in ground-breaking Research and Development projects at the DePuy Synthes Ireland Innovation Centre based in Loughbeg, Ringaskiddy, Co. Cork. This 5-year project will result in significant developments at the company’s Materials and Surface Technology Centre, including co-location with Johnson & Johnson’s 3D Printing Center of Excellence, creating 30 additional high-quality pharmaceutical jobs in Ireland.  Full article >>

Regeneron set to create hundreds of new jobs following €200m investment at Limerick facility

Hundreds of new jobs are on the way for Limerick as Regeneron plan to invest €200m at it’s Raheen facility. The expansion plans include an extension to its current manufacturing facilities, build of an admin building with state-of-the-art Research and Development facilities in Limerick and a multi storey car park with 800 spaces. Full article >>

Global News

Bristol-Myers Squibb to buy Celgene for $74bn

BMS has announced plans to acquire Celgene, in a deal costing approx. €74bn, creating a pharma company with several blockbuster cancer drugs and making it one of the biggest mergers on record in the sector. The deal will create a company with nine treatments bringing in more than $1 billion in annual sales with significant potential for growth in oncology, immunology and inflammation and cardiovascular disease. The companies expect to close the deal in the third quarter of this year. Full article >>

Start typing and press Enter to search